Enterprise Associates 14, L... Net Worth

The estimated Net Worth of Enterprise Associates 14, L... is at least $21 Million dollars as of 5 March 2019. Enterprise L owns over 3,750,000 units of Mersana Therapeutics Inc stock worth over $21,045,544 and over the last 6 years Enterprise sold MRSN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Enterprise L MRSN stock SEC Form 4 insiders trading

Enterprise has made over 1 trades of the Mersana Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Enterprise bought 3,750,000 units of MRSN stock worth $15,000,000 on 5 March 2019.

The largest trade Enterprise's ever made was buying 3,750,000 units of Mersana Therapeutics Inc stock on 5 March 2019 worth over $15,000,000. On average, Enterprise trades about 3,750,000 units every 0 days since 2019. As of 5 March 2019 Enterprise still owns at least 11,890,138 units of Mersana Therapeutics Inc stock.

You can see the complete history of Enterprise L stock trades at the bottom of the page.

Insiders trading at Mersana Therapeutics Inc

Over the last 7 years, insiders at Mersana Therapeutics Inc have traded over $1,068,087 worth of Mersana Therapeutics Inc stock and bought 26,457,775 units worth $226,822,416 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, Mersana Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $534,621. The most recent stock trade was executed by Anna Protopapas on 13 January 2024, trading 86,958 units of MRSN stock currently worth $153,916.

What does Mersana Therapeutics Inc do?

mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

Complete history of Enterprise L stock trades at Mersana Therapeutics Inc

Mersana Therapeutics Inc executives and stock owners

Mersana Therapeutics Inc executives and other stock owners filed with the SEC include:

• Anna Protopapas,
  President, Chief Executive Officer, Director
• Dirk Huebner,
  Chief Medical Officer
• Timothy Lowinger,
  Chief Science and Technology Officer
• Brian DeSchuytner,
  Senior Vice President - Finance and Product Strategy
• Anna Protopapas,
  Pres, CEO & Director
• Anna Protopapas M.B.A.,
  Pres, CEO & Director
• Dr. Timothy B. Lowinger,
  Chief Science & Technology Officer
• Brian C. DeSchuytner,
  Sr. VP & CFO
• Dr. Arvin Yang M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Alejandra Veronica Carvajal J.D.,
  SVP, Sec. & Chief Legal Officer
• Dr. Tushar Misra Ph.D.,
  SVP & Chief Manufacturing Officer
• David Mott,
  Independent Chairman of the Board
• Lawrence Alleva,
  Independent Director
• Willard Dere,
  Independent Director
• Andrew Hack,
  Independent Director
• Kristen Hege,
  Independent Director
• Martin Huber,
  Independent Director
• Eva Jack,
  Chief Business Officer
• Chuck Miller,
  Senior Vice President - Regulatory Affairs
• Michael Kaufman,
  Senior Vice President - Chemistry, Manufacturing and Controls
• Alejandra Veronica Carvajal,
  Sr. VP & Chief Legal Officer
• Carla Poulson,
  Chief HR Officer
• Radha Iyengar,
  VP of Legal Operations
• Sarah Carmody,
  Exec. Director of Investor Relations & Corp. Communications
• Ashish Mandelia,
  VP, Controller & Principal Accounting Officer
• Mikhail Papisov Ph.D.,
  Co-Founder
• Llc Fmr,
  
• Peter J Barris,
  10% owner
• Forest Baskett,
  10% owner
• M James Barrett,
  10% owner
• Ravi Viswanathan,
  10% owner
• Peter W. Sonsini,
  10% owner
• Enterprise Associates 14, L...,
  
• Patrick J Kerins,
  10% owner
• Scott D Sandell,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Sara M. Nayeem,
  Director
• Wayne Foster,
  Vice President of Finance
• Donald A Bergstrom,
  Chief Medical Officer
• David A Spellman,
  Chief Financial Officer
• Enterprise Associates 14, L...,
  
• Partners 14, L.P.Nea 14 Gp,...,
  
• Enterprise Associates 14, L...,
  
• Enterprise Associates 14, L...,
  10% owner
• Allene M. Diaz,
  Director
• Mohan Bala,
  SVP, Chief Development Officer
• Arvin Yang,
  SVP, Chief Medical Officer
• Ashish Mandelia,
  VP, Chief Accounting Officer
• Tushar Misra,
  SVP, Chief Manuf. Officer